ZA200508733B - Muscarinic M1 receptor agonists for pain management - Google Patents

Muscarinic M1 receptor agonists for pain management

Info

Publication number
ZA200508733B
ZA200508733B ZA200508733A ZA200508733A ZA200508733B ZA 200508733 B ZA200508733 B ZA 200508733B ZA 200508733 A ZA200508733 A ZA 200508733A ZA 200508733 A ZA200508733 A ZA 200508733A ZA 200508733 B ZA200508733 B ZA 200508733B
Authority
ZA
South Africa
Prior art keywords
muscarinic
receptor agonists
pain management
pain
management
Prior art date
Application number
ZA200508733A
Other languages
English (en)
Inventor
Rober E Davis
Mario Rodriguez
Kimberley Vanover
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Publication of ZA200508733B publication Critical patent/ZA200508733B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ZA200508733A 2003-03-28 2005-10-27 Muscarinic M1 receptor agonists for pain management ZA200508733B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45904503P 2003-03-28 2003-03-28

Publications (1)

Publication Number Publication Date
ZA200508733B true ZA200508733B (en) 2006-09-27

Family

ID=33131858

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200508733A ZA200508733B (en) 2003-03-28 2005-10-27 Muscarinic M1 receptor agonists for pain management

Country Status (13)

Country Link
US (1) US20050130961A1 (enExample)
EP (1) EP1613321A2 (enExample)
JP (1) JP2006521399A (enExample)
KR (1) KR20050112116A (enExample)
CN (1) CN1777425A (enExample)
AU (1) AU2004226430A1 (enExample)
BR (1) BRPI0409523A (enExample)
CA (1) CA2520125A1 (enExample)
MX (1) MXPA05010171A (enExample)
NZ (1) NZ542690A (enExample)
RU (1) RU2358735C2 (enExample)
WO (1) WO2004087158A2 (enExample)
ZA (1) ZA200508733B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7307075B2 (en) * 2001-12-28 2007-12-11 Acadia Pharmaceuticals Inc. Tetrahydroquinoline analogues as muscarinic agonists
US7550459B2 (en) * 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
KR20070036149A (ko) * 2004-07-16 2007-04-02 얀센 파마슈티카 엔.브이. 이량체 피페리딘 유도체
AU2006282896A1 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
ES2573253T3 (es) 2006-09-20 2016-06-06 The Board Of Regents Of The University Of Texas System Métodos para el suministro de anestésicos volátiles para anestesia regional y/o alivio del dolor
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
CN107661293A (zh) 2008-01-22 2018-02-06 得克萨斯大学体系董事会 用于局部麻醉和/或疼痛缓解的含有萃取溶剂的挥发性麻醉剂组合物
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CA2772488C (en) 2009-09-11 2018-04-17 Probiodrug Ag Heterocyclic derivatives as inhibitors of glutaminyl cyclase
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
KR20150143439A (ko) * 2013-03-15 2015-12-23 알레간 인코포레이티드 무스카린성 효능제
KR102349237B1 (ko) 2014-04-23 2022-01-07 다케다 야쿠힌 고교 가부시키가이샤 알츠하이머 병의 치료를 위한 콜린작동성 무스카린 ｍ１ 수용체 양성 알로스테릭 조절인자 활성을 갖는 이소인돌린-1-온 유도체
TN2017000508A1 (en) 2015-06-26 2019-04-12 Takeda Pharmaceuticals Co 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
JP6787913B2 (ja) 2015-10-20 2020-11-18 武田薬品工業株式会社 複素環化合物
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
CA3131128A1 (en) * 2019-02-22 2020-08-27 Karuna Therapeutics, Inc. Compounds and methods of deuterated xanomeline for treating neurological disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8717446D0 (en) * 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US5155166A (en) * 1990-06-18 1992-10-13 Eastman Kodak Company Use of 1-(1-pyrrolidinylcarbonyl)pyridinium salts to attach compounds to carboxylated particles and a kit containing same
FR2663929A1 (fr) * 1990-06-29 1992-01-03 Adir Nouveaux derives d'oxazolo pyridines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
IL110298A (en) * 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
GB2292685A (en) * 1994-07-27 1996-03-06 Sankyo Co Allosteric effectors at muscarinic receptors
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
FR2747041B1 (fr) * 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
US6528529B1 (en) * 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
AU1596099A (en) * 1998-11-23 2000-06-13 Eisai Co. Ltd. Aryl and heteroaryl compounds useful as fibroblast growth factor antagonists
BR0110420A (pt) * 2000-04-28 2003-07-01 Acadia Pharm Inc Agonistas muscarìnicos
ATE516030T1 (de) * 2001-10-02 2011-07-15 Acadia Pharm Inc Benzimidazolidinon-derivate als muscarinische mittel
US7307075B2 (en) * 2001-12-28 2007-12-11 Acadia Pharmaceuticals Inc. Tetrahydroquinoline analogues as muscarinic agonists

Also Published As

Publication number Publication date
AU2004226430A1 (en) 2004-10-14
WO2004087158A2 (en) 2004-10-14
RU2358735C2 (ru) 2009-06-20
RU2005133197A (ru) 2006-04-27
WO2004087158A3 (en) 2005-03-31
CN1777425A (zh) 2006-05-24
BRPI0409523A (pt) 2006-04-18
US20050130961A1 (en) 2005-06-16
CA2520125A1 (en) 2004-10-14
JP2006521399A (ja) 2006-09-21
MXPA05010171A (es) 2005-12-12
EP1613321A2 (en) 2006-01-11
NZ542690A (en) 2009-04-30
KR20050112116A (ko) 2005-11-29

Similar Documents

Publication Publication Date Title
ZA200508733B (en) Muscarinic M1 receptor agonists for pain management
AP1828A (en) Muscarinic Acetycholine receptor antagonists
ZA200605843B (en) Centralized medication management system
GB0703133D0 (en) Wire management device
AU2003228485A8 (en) Farnesoid x-activated receptor agonists
AU2003287880A1 (en) Cyclic quinoline compounds for use in mch receptor related disorders
AU2003229006A8 (en) Prescription management system with pharmaceutical sample distribution
PL377495A1 (pl) Stały lek do stosowania doustnego
GB0315541D0 (en) Project management
AU2003248356A1 (en) Beta3-adrenergic receptor agonists
IL174056A0 (en) Novel adenosine a3 receptor agonists
AU2003280675A1 (en) SELECTIVE HUMAN Beta3 ADRENALIN RECEPTOR AGONIST AGENT
GB2420964B (en) Cable management arm
SG131946A1 (en) Ccr3 receptor antagonists
SG118330A1 (en) Management device for excess cabling
HK1087342A (en) Muscarinic m1 receptor agonists for pain management
EP1636230A4 (en) ADENOSINE A1 RECEPTOR ANTAGONISTS
IL173337A0 (en) Receptor
GB2392081B (en) Adjustable cable management arm for furniture
GB2402797B (en) Integrated traffic management system
GB0408398D0 (en) Leptin receptor agonists (3)
GB0408454D0 (en) Leptin receptor agonists (1)
AU2003249621A8 (en) Hemipteran muscarinic receptor
GB0408453D0 (en) Leptin receptor agonists
IL155112A0 (en) Technique for network management